ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00344487
Recruitment Status : Terminated (Inability to enroll subjects.)
First Posted : June 26, 2006
Results First Posted : December 19, 2014
Last Update Posted : March 21, 2018
Sponsor:
Information provided by (Responsible Party):
Charles E. Davis, Jr., University of Maryland

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: HIV
Intervention: Drug: Lopinavir/Ritonavir

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
This study received IRb approval on 12/7/05. Recruitment was difficult and the inclusion criteria was amended in November 2007 to help increase enrollment.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Kaletra Lopinavir/Ritonavir (Kaletra) 400/100 mg by mouth twice a day for 48 weeks.

Participant Flow:   Overall Study
    Kaletra
STARTED   3 
COMPLETED   2 [1] 
NOT COMPLETED   1 
immunologic failure                1 
[1] One subject was withdrawn at month 9 because he was considered an immunologic failure on study.



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Kaletra Lopinavir/Ritonavir (Kaletra) 400/100 mgby mouth twice a day for 48 weeks

Baseline Measures
   Kaletra 
Overall Participants Analyzed 
[Units: Participants]
 3 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      3 100.0% 
>=65 years      0   0.0% 
Age 
[Units: Years]
Mean (Standard Deviation)
 43  (3) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      0   0.0% 
Male      3 100.0% 
Region of Enrollment 
[Units: Participants]
 
United States   3 


  Outcome Measures

1.  Primary:   Changes From Baseline in CD4 Cell Percentage at 6 and 12 Months   [ Time Frame: Baseline, 6 and 12 months ]

2.  Primary:   Absolute Change in CD4 Cell Count From Baseline, and at 6 and 12 Months   [ Time Frame: 6 and 12 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

3.  Primary:   Changes From Baseline in CD4 Cell Count at 6 and 12 Months   [ Time Frame: 6 and 12 months ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  

4.  Primary:   Baseline Will be Defined as the Mean of 2 Values Obtained Prior to the Medication Switch (for Analysis Purposes, the CD4 Cell Counts at 6 and 12 Months Will be Defined by the Mean of the CD4 Cell Counts Obtained at Months 3, 6 or 9, 12, Respectively).   [ Time Frame: 3, 6, 0r 9, 12 months respectively ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
We screened and enrolled a total of three participants. Two of the three participants completed the study. Unable to meet the stated goals of the study, it was decided that it should be closed.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Charles E. Davis, Jr. MD
Organization: University of Maryland Institute of Human Virology
phone: 410-706-1684
e-mail: cdavis@ihv.umaryland.edu



Responsible Party: Charles E. Davis, Jr., University of Maryland
ClinicalTrials.gov Identifier: NCT00344487     History of Changes
Other Study ID Numbers: H-27050
First Submitted: June 22, 2006
First Posted: June 26, 2006
Results First Submitted: August 3, 2012
Results First Posted: December 19, 2014
Last Update Posted: March 21, 2018